Emergence and Spread of Streptococcus pneumoniae with erm(B) and mef(A) Resistance
David J. Farrell*

, Stephen G. Jenkins†, Steven D. Brown‡, Manish Patel§, Bruce S. Lavin§, and Keith P. Klugman¶#
Author affiliations: *G.R. Micro Ltd, London, United Kingdom; †Mount Sinai School of Medicine, New York, New York, USA; ‡Clinical Microbiology Institute, Wilsonville, Oregon, USA; §sanofi-aventis, Bridgewater, New Jersey, USA; ¶Emory University, Atlanta, Georgia, USA; #University of the Witwatersrand, Johannesburg, South Africa
Main Article
Table 2
Proportion of erythromycin-resistant Streptococcus pneumoniae isolates collected from years 1 to 3 of the PROTEKT US study with the dual mef(A)+erm(B) genotype according to patient age
Patient age (y) |
No. erm(B)+mef(A)–positive/no. erythromycin-resistant (%)
|
Year 1 |
Year 2 |
Year 3 |
0–2 |
88/825 (10.7) |
118/640 (18.4) |
170/710 (23.9) |
3–14 |
52/388 (13.4) |
47/365 (12.9) |
84/409 (20.5) |
15–64 |
98/1,106 (8.9) |
95/972 (9.8) |
151/1,173 (12.9) |
>64 |
58/727 (8.0) |
70/755 (9.3) |
98/794 (12.3) |
Not specified
|
8/87 (9.2)
|
5/61 (8.2)
|
17/91 (18.7)
|
Total |
304/3,133 (9.7) |
335/2,793 (12.0) |
520/3,177 (16.4) |
Main Article
Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.